Results 291 to 300 of about 914,390 (333)

Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. [PDF]

BMC Psychiatry
IsHak WW, Hirsch D, Renteria S, Totlani J, Murphy N, Chang T, Abdelsalam R, Salem M, Meyer A, Keerthana S, Liu A, Contreras L, Tadros E, Hedrick R, Danovitch I, Pechnick RN.   +15 more
europepmc   +1 more source

FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials. [PDF]

Clin Cancer Res
Shord SS, Chen C, Jin JY, Van Wart S, Martin SK, Davidson BA, Liu J, LoRusso PM, Oxnard GR.   +8 more
europepmc   +1 more source

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. [PDF]

Clin Cancer Res
Maguire WF, Chi DC, Agrawal S, Joeng HK, Kim-McOlash S, Manheng W, Bulatao I, Sanchez-Solana B, Pathak A, Lee A, Han Y, Ricks TK, Hamed SS, Fiero MH, Pierce WF, Kalavar S, Ghosh S, Leighton JK, Tang S, Amiri-Kordestani L, Kluetz PG, Suzman DL.   +21 more
europepmc   +1 more source

Regenerative Medicine: Tremendous Potential but Not Quite Ready for Prime-Time. [PDF]

HSS J
Rodeo SA.
europepmc   +1 more source

Research and development investments for biologics independently developed by US biotechnology startups, 2017-2023. [PDF]

Health Aff Sch
Odouard IC, Kang SY, Mo J, Anderson GF, Alexander GC.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

23andMe and the FDA

New England Journal of Medicine, 2014
Because of a warning from the FDA, 23andMe has stopped marketing its personal genome service. Now, a dialogue about key issues in genomic testing could result in clear standards for the industry, including requirements for informed consent and disclosure of results.
Koichiro Yuji, Yasuo Oshima, Tetsuya Tanimoto   +2 more
openaire   +6 more sources

FDA finds that FDA is not biased [PDF]

Chemical & Engineering News Archive, 1975
Following a year-long in-house investigation of employee allegations that the Food & Drug Administration is biased toward the drug industry, Commissioner Alexander M. Schmidt has concluded that not only is there "no evidence to support such charges," but that "there is evidence to refute them." In a 906-page report issued earlier this month, Dr ...
openaire   +1 more source